FIRST IN A NEW CLASS OF TREATMENT IN AUSTRALIA FOR ENDOMETRIOSIS & UTERINE FIBROIDS1
Ryeqo is a GnRH antagonist combined with add-back therapy in a single, once-daily pill1
Designed to delicately balance efficacy & safety:1,2
Ryeqo is indicated in adult women of reproductive age for:1
Symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis
Treatment of moderate to severe symptoms of uterine fibroids
Endometriosis Education Program
This comprehensive education program is designed for primary care practitioners (including GPs and nurses).
Learn more
Abbreviations: ABT, add-back therapy; BMD, bone mineral density; E2, estradiol; GnRH, gonadotropin-releasing hormone.
References:
- Ryeqo Approved Product Information. January 2024.
- Giudice LC et al. Lancet. 2022;399:2267–2279.